USCWA
AZN icon

U.S. Capital Wealth Advisors’s AstraZeneca AZN Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.68M Buy
8,532
+82
+1% +$15.8K 0.04% 387
2025
Q4 		$1.55M Buy
8,450
+184
+2% +$32.3K 0.04% 388
2025
Q3 		$1.27M Buy
8,266
+135
+2% +$20.4K 0.03% 426
2025
Q2 		$1.14M Buy
8,131
+389
+5% +$54.5K 0.03% 404
2025
Q1 		$1.14M Buy
7,742
+5,275
+214% +$763K 0.03% 400
2024
Q4 		$323K Buy
2,467
+504
+26% +$70.6K 0.01% 666
2024
Q3 		$306K Sell
1,963
-453
-19% -$73.1K 0.01% 582
2024
Q2 		$377K Buy
2,416
+109
+5% +$16.4K 0.01% 515
2024
Q1 		$313K Sell
2,307
-462
-17% -$61.2K 0.01% 559
2023
Q4 		$373K Buy
2,769
+904
+48% +$118K 0.01% 508
2023
Q3 		$253K Sell
1,865
-437
-19% -$59.7K 0.01% 553
2023
Q2 		$330K Buy
2,302
+43
+2% +$6.33K 0.02% 514
2023
Q1 		$314K Buy
2,259
+1,407
+165% +$189K 0.01% 525
2022
Q4 		$115K Buy
+852
New +$107K 0.01% 714

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

U.S. Capital Wealth Advisors's AZN Position: Q1 2026 in Review

U.S. Capital Wealth Advisors increased its AstraZeneca (AZN) stake by 0.97% in Q1 2026, buying an estimated $15.8K and bringing the position to 8,532 shares worth $1.68M. The position accounts for 0.04% of the portfolio, ranked #387.

U.S. Capital Wealth Advisors first reported a position in AZN in Q4 2022 and has held it in 14 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • U.S. Capital Wealth Advisors held 8,532 shares of AstraZeneca worth $1.68M as of Q1 2026.
  • U.S. Capital Wealth Advisors bought 82 AstraZeneca shares in Q1 2026, an estimated $15.8K.
  • AstraZeneca made up 0.04% of U.S. Capital Wealth Advisors's portfolio in Q1 2026, its #387 holding.
  • U.S. Capital Wealth Advisors first reported a position in AstraZeneca in Q4 2022 and has held it in 14 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.